Skip to content

At-home Breast Oncology Care Delivered With E-health Solutions

Patient Reported Outcome Measures | Patient Engagement | Patient Activation

The COVID-19 pandemic has significantly impacted healthcare service delivery, highlighting the need for high quality virtual patient care. Our team has developed a multi-dimensional remote eHealth solution for newly diagnosed breast cancer patients and their practitioners to use during the diagnostic and follow-up period. The ABODE study involved development of a Breast Cancer Treatment Application (app) which will facilitate virtual consultations, deliver patient education material, and collect patient reported outcome measures (PROMs). Using a randomized controlled trial design, the team will evaluate a variety of outcomes for breast cancer patients who will use the app throughout their diagnosis and treatment period.

Primary Objective: To compare changes in patient activation (assessed by PAM-13) over 1 year among newly diagnosed breast cancer patients between those using the app and those receiving standard care.

Secondary Objectives:

1. Compare additional PROMs between the standard care and intervention groups
2. Describe health service outcomes among app users
3. Explore end-user experience of using the app
4. Measure activity levels using wearable devices

null

Participation Requirements

  • Sex:

    FEMALE

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Females (assigned female at birth)\*
* Diagnosed with first, primary invasive BC
* Must have surgery as their first step in treatment pathway
* Age≥18
* Access to an electronic device with connection to the internet
* A valid email address
* Can communicate in English \*Since BC risk is sex-related and based on physiological values, our inclusion criteria are based on sex (not gender)

Exclusion criteria:

* Males (assigned male at birth), as BC surgical treatment options and experiences are different
* Diagnosed with non-operable breast cancer
* Stage 4/metastatic (whether determined at diagnosis or during surgery)
* Those with hearing or visual challenges
* Neo-adjuvant chemotherapy
* Should not be enrolled in any other UHN study using an e-Health application
* Breast cancer surgery is scheduled for less 5 business days after enrollment

Study Location

Tulin Cil
Tulin Cil
Toronto, Ontario
Canada

Contact Study Team

Backup Contact

Emma Reel, MSW

[email protected]
6472021028
Primary Contact

Tulin Cil, MD, MEd

[email protected]
4169464507
Study Sponsored By
University Health Network, Toronto
Participants Required
More Information
Study ID: NCT05989477